KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,296,857 | +21.5% | 650,366 | -1.5% | 0.72% | +36.2% |
| Q2 2023 | $9,294,546 | +31.7% | 660,124 | +0.7% | 0.53% | +31.4% |
| Q1 2023 | $7,054,859 | -32.4% | 655,656 | -6.0% | 0.40% | -33.1% |
| Q4 2022 | $10,443,487 | +8.5% | 697,162 | -7.0% | 0.60% | +7.3% |
| Q3 2022 | $9,629,000 | +22.0% | 749,933 | -7.9% | 0.56% | +46.1% |
| Q2 2022 | $7,894,000 | -2.2% | 814,673 | +0.3% | 0.38% | +18.6% |
| Q1 2022 | $8,071,000 | -3.8% | 811,922 | +13.9% | 0.32% | +8.1% |
| Q4 2021 | $8,390,000 | -0.1% | 712,807 | -3.3% | 0.30% | -3.9% |
| Q3 2021 | $8,399,000 | -17.9% | 737,374 | +0.4% | 0.31% | -14.8% |
| Q2 2021 | $10,230,000 | -17.1% | 734,366 | +10.2% | 0.36% | -9.5% |
| Q1 2021 | $12,334,000 | +16.4% | 666,353 | +11.1% | 0.40% | +7.8% |
| Q4 2020 | $10,593,000 | – | 599,517 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |